Floatz logo

Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma

Explore 27 assets in B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma →
Floatz Rating
CC43/100
Confidence
Indicative
v0.2
Sponsor
City of Hope Medical Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT02153580CT.gov
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma

AssetSponsorPhaseRating
Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes (this asset)City of Hope Medical CenterP1CC · 43
CyclophosphamideUniversity of WashingtonP2BB
RituximabUniversity of WashingtonP2BB
EtoposideUniversity of WashingtonP2BB
AdriamycinUniversity of WashingtonP2BB
PrednisoneUniversity of WashingtonP2BB
(+)-VincristineCity of Hope Medical CenterP2B
OndansetronUNC Lineberger Comprehensive Cancer CenterP2B
PembrolizumabSeda S. ToluP2B

+29 more in the B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma cohort

Other indications for Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes

IndicationSponsorPhaseRating
Mantle Cell Lymphoma—P1CC · 43
Non-Hodgkin Lymphoma—P1CC · 43
B-Cell Prolymphocytic Leukemia—P1CC · 43

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes in B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/autologous-cd19car-cd28-cd3zeta-egfrt-expressing-tnmem-enriched-t-lymphocytes-b-cell-lymphoma-unclassifiable-with-features-intermediate-between-diffuse-large-b-cell-lymphoma-and-classical-hodgkin-lymphoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →